Annoroad

Annoroad Gene Technology, established in 2012 with its headquarters in Beijing, is a well-known enterprise in China's genomics industry, a leading NIPT service provider in China, and a top-tier medical genomics center in Asia. It focuses on the industrial application of next-generation genomic technologies in two major fields: human medical health and life science research.Since its inception, Annoroad has been recognized as a National High-tech Enterprise, one of the first pilot units by the National Health Commission for clinical application of high-throughput gene sequencing technology, one of the first demonstration centers by the National Development and Reform Commission for gene detection technology applications, the Precision Medicine and Genome Engineering Laboratory of Beijing by the Beijing Municipal Development and Reform Commission, a Zhongguancun High-tech Enterprise, one of the first enterprises in the G20 Project for Beijing’s biomedical industry leapfrog development during the "13th Five-Year Plan" period, a Beijing Science and Technology Research Institution, a Beijing Patent Pilot Unit, a Beijing Intellectual Property Demonstration Unit, and a Beijing Enterprise Technology Center. It also hosts a postdoctoral research workstation. Annoroad was selected among the Deloitte–Yizhuang Top 20 High-tech and High-growth Companies, the Top 30 Chinese Enterprises with the Most Technological Leadership, and the Top 50 Chinese Enterprises with the Most Investment Value. In the field of medical health, Annoroad has launched a series of outstanding high-throughput sequencing medical testing and research projects in reproductive health, oncology diagnosis and treatment, and genetic wellness, including non-invasive prenatal DNA testing, chromosomal abnormality testing, ctDNA testing, and hematology gene testing, which have received accreditation from authoritative domestic and international organizations (NCCN, CAP, etc.).